Objective:This study aimed to detect the expression of annexin A1 in human non-small cell lung cancer (NSCLC) and to explore its clinical significance. Methods:We detected the expression levels of annexin A1 in NSCLC and the same patient's dis-tal cancerous tissue (from the edge of the tumor >5 cm) by real-time fluorescence quantitative polymerase chain reaction (real-time PCR), Western blot, and immunohistochemical methods, and then analyzed their correlation with clinical pathological parameters. Re-sults: Real-time PCR showed that the expression of annexin A1 mRNA in NSCLC was higher than that of distal cancerous tissue (0.574±1.403 vs. 0.240±0.893, t=2.060, P=0.045). Moreover, the expression of annexin A1 in NSCLC was associated with the degree of differentiation, lymph node metastasis, and TNM staging (P<0.05), but independent of gender, age, smoking history, tumor size, and histological type (P>0.05). Western blot and immunohistochemistry revealed that the expression of annexin A1 protein in NSCLC was higher than that of distal cancerous tissue. Conclusion:Annexin A1 is highly expressed in the cancer tissues of patients with NSCLC, which may be correlated with the occurrence and development of tumor and its invasion and metastasis.

Objective To investigate the inhibitory effect of rhIFN-γ on human chronic myeloid leukemia cell line K562,and the impaction on the expression of CD123.Methods MTT method was used to test cell relative viability with rhIFN-γ at different concentrations.The expression of CD123 on K562 ceils was detected by flow cytometry.Results The relative inhibition of K562 cells proliferation was hampered when the cells were treated with rhIFN-γ for 72 h at the concentration of 5 x 10P ～ 108 U/L,respectively.However,rhIFN-γ at 2 x 105 U/L was benefit to K562 cells proliferation.After treatment with rhIFN-γ at 0,2 x 105 U/L and 107 U/L,the percentages of CD123 expression on K562 cells were (4.10 ± 1.46) ％,(7.2 ± 2.50) ％ as well as (21.6 ± 1.17) ％,respectively.Compared with the control group,107 U/L rhIFN-γ significantly increased the expression of CD123 on K562 cells (P＜0.05).Conclusion The effect of rhIFN-γ on the growth of K562 cells has two aspects (inhibition or proliferation),and it can increase the expression of CD 123.

Pain is a common non-motor symptom in Parkinson's disease (PD) patients, incidence of which is high. PD patients with pain are not only prone to anxiety, depression, sleep disorders and other non-motor symptoms, but also accompanied with motor complications, causing the quality of life declined. The gamma-aminobutyric acid (GABA) neurotransmitters participate in the conduction of sensory pathways in the central nervous system. PD patients were also found that GABA regulation of the sensory pathway is impaired, indicating that GABA is also involved in the occurrence of central pain in PD. In this article we aim to elucidate the role of GABA in the central sensory pathway, and the pathological anatomy, animal anatomy, clinical image and clinical application of GABA damage in pain-related sensory pathways in PD.

Objective:To investigate the expression of macrophage migration inhibitory factor (MIF) in bone marrow fluid and peripheral blood of patients with acute myeloid leukemia (AML) and its effect on the expression of interleukin-8 (IL-8) in bone marrow mesenchymal stem cells (BM-MSC).Methods:Fifty bone marrow fluid samples and 50 peripheral blood samples were collected from 50 patients with AML diagnosed in the First People's Hospital of Yunnan Province from October 2017 to January 2019, of which 17 patients were newly diagnosed, 26 patients were complete remission (CR), and 7 patients were partial remission (PR) or non-remission (NR). Fifty plasma samples from 50 healthy subjects and 50 bone marrow fluid samples from 50 patients with iron deficiency anemia were used as the controls. Enzyme-linked immunosorbent assay (ELISA) was used to detect the level of MIF protein in the samples, and the relationship between MIF expression level and clinicopathological characteristics of AML patients was analyzed. BM-MSC was successfully isolated and cultured from 42 bone marrow fluid samples of AML patients, the suitable samples for experiment were chosen and divided into BM-MSC control group (untreated BM-MSC), recombinant human macrophage migration inhibitory factor (rhMIF) group and rhMIF+ISO-1 group. ELISA and real-time fluorescence quantitative polymerase chain reaction were used to detect the expression level of IL-8 protein and mRNA in each BM-MSC group.Results:The expression levels of MIF protein in bone marrow fluid and plasma in AML group were (24.9±7.7) ng/ml and (60.5±12.1) ng/ml, the difference was statistically significant ( P < 0.01), and those in control group were (5.3±2.6) ng/ml and (2.0±1.1) ng/ml, respectively, and there were statistical differences between the two groups (t values were 136.71, 33.97 and 17.58, all P < 0.01). MIF protein expression levels in bone marrow fluid and plasma of AML patients in newly diagnosed group and PR+NR group were higher than those in CR group, and the differences were statistically significant (all P < 0.01). MIF protein expression levels were higher in bone marrow fluid and plasma of patients with ≥60 years of age, peripheral blood white blood cell count ≥30×10 9/L and bone marrow myeloblast ratio > 0.50 (all P < 0.05), but the differences were not statistically significant between patients with different gender (both P > 0.05). The detection results of each BM-MSC group showed that rhMIF promoted the IL-8 expression in BM-MSC at the gene and protein levels, which could be inhibited by the MIF inhibitor ISO-1 (all P < 0.01). Conclusion:The increased expression levels of MIF in bone marrow fluid and plasma of patients with AML are associated with the disease progression, and rhMIF can promote the expression of IL-8 in BM-MSC.